Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...

Prasad's stint included several controversial vaccine decisions; the FDA is now searching for a new head for its vaccine division.

Findings seen in pilot study of older adults with mild cognitive impairment, but other coprimary outcomes did not meet significance thresholds.

A Prescription Drug User Fee Act target date of December 22, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

In addition, GLP-1 receptor agonist initiation linked to reduced risks for SUD-related adverse events for people with preexisting SUD.

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

Tazverik is withdrawn for all indications, including follicular lymphoma and epithelioid sarcoma, following unfavorable trial safety data.

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of deucravacitinib in adults aged 18 years and older with active PsA.

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Kennedy Jr. announced a new effort Thursday aimed at getting medical schools to spend more time teaching students about nutrition.

The FDA is expected to decide on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity.